Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 10:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 241 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: T2DM (Type 2 Diabetes Mellitus) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

NCT06279234
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Obesity
Interventions
Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 30, 2026, 10:33 PM EDT
Terminated Not applicable Interventional

Feasibility Testing an Exercise Program to Improve Cognition for T2DM Patients

NCT04590833
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Supervised walking on a treadmill, Supervised stretching exercise
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

NCT01794364
View directory record Official record
Conditions
Healthy
Interventions
PF-06291874, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Not applicable Interventional

The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes

NCT01648244
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
Computer-Assisted Decision Support
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 30, 2026, 10:33 PM EDT
Enrolling by invitation No phase listed Observational

Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)

NCT07197775
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Type2Diabetes, Diabetes Mellitus, Type 2, Type 2 Diabetes, Diabetes
Interventions
Not listed
Lead sponsor
Endogenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Quincy, Massachusetts • Raleigh, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 4 Interventional Results available

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

NCT02981069
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Exenatide, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Results available

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

NCT02554877
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-06291874, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Anaheim, California • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

NCT03882970
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
33
States / cities
Little Rock, Arkansas • Fresno, California • Huntington Park, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 1 Interventional

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

NCT00768105
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2010 · Synced Sep 30, 2026, 10:33 PM EDT
Recruiting Not applicable Interventional

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

NCT06906627
View directory record Official record
Conditions
Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
Interventions
(IRIS-CKD Screening Program): Home Kit, (IRIS-CKD Screening Program): Standard Lab Order
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 30, 2026, 10:33 PM EDT
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

NCT04754334
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
ORMD-0801, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 30, 2026, 10:33 PM EDT
Recruiting Not applicable Interventional

OASIS: Peer Support for T2DM in Appalachia (Peer Participant)

NCT06336122
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Peer Coach Training - Weekly, Peer Coach Training - Biweekly
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bowling Green, Kentucky • Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

NCT01002807
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Dapagliflozin, Metformin XR, Glucophage
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 2 Interventional

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

NCT03604419
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
PB-119 100 μg+ Glucophage®, PB-119 150 μg+ Glucophage®, PB-119 200 μg+ Glucophage®, PB-119 placebo + Glucophage®
Drug
Lead sponsor
PegBio Co., Ltd.
Other
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Sep 30, 2026, 10:33 PM EDT
Enrolling by invitation Not applicable Interventional

Population Health Management for KPNC Members With Newly Diagnosed Diabetes: A Randomized Trial of a Proactive and Augmented Initial Care Strategy

NCT06906653
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes (T2D)
Interventions
Augmented Initial Type 2 Diabetes Care
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 74 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pfizer/IVGTT/Ziprasidone/Olanzapine

NCT00205725
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Not applicable Interventional

Examining The Role of CGM in T2DM

NCT01614262
View directory record Official record
Conditions
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions
Continuous Glucose Monitoring with treatment algorithm
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 1 Interventional

A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT04143802
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3437943, Dulaglutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Lenexa, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 1 Interventional

CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)

NCT04990427
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
CLBS201
Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 30, 2026, 10:33 PM EDT
Recruiting Not applicable Interventional

OASIS: Peer Support for T2DM in Appalachia (Peer Coaches)

NCT06003634
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Peer Coaching - Peer Participants A, Peer Coaching - Peer Participants B, Peer Coaching - Peer Participants C, Peer Coaching - Peer Participants D
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bowling Green, Kentucky • Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

NCT01221545
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

NCT06305351
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus (T2DM)
Interventions
K-757 and K-833 QD, K-757 and K-833 BID, Matching placebo to K-757 and K-833 QD, Matching placebo to K-757 and K-833 BID
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers

NCT00501397
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
ketoconazole, GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Sep 30, 2026, 10:33 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Sep 30, 2026, 10:33 PM EDT